SCHEMBL2294067

SCHEMBL2294067

C=C[Si](O)(CCCC)CCCC

nearest known ligand 0.38

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.38
ALDH1A1 P00352 2/20 0.38
ZDHHC20 Q5W0Z9 1/20 0.34
ZDHHC2 Q9UIJ5 1/20 0.34
FAAH O00519 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292616 0.95 TSHR (0.35) TSHRALDH1A1ZDHHC20ZDHHC2FAAH
SCHEMBL2292102 0.90 TSHR (0.35) TSHRALDH1A1ZDHHC20ZDHHC2FAAH
SCHEMBL2288387 0.83 TSHR (0.32) TSHR
SCHEMBL29179306 0.81 TSHR (0.39) TSHRALDH1A1ZDHHC20ZDHHC2FAAH
SCHEMBL15302506 0.79
SCHEMBL3482708 0.79 TSHR (0.38) TSHRALDH1A1ZDHHC20ZDHHC2FAAH
SCHEMBL2292627 0.77
SCHEMBL2285686 0.75 EPHX2 (0.36) FAAHHPGD
SCHEMBL3482564 0.75
SCHEMBL29156496 0.75 TSHR (0.43) TSHRALDH1A1ZDHHC20ZDHHC2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268489-B2 Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same LG CHEM, LTD. (KR) 2012-09-18 US claimed
US-20110206999-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2011-08-25 US claimed
WO-2019164083-A1 FILTER UNIT FOR FLUID SET 대가파우더시스템(주) 2019-08-29 WO disclosed
EP-2128897-B1 SILICON DIELECTRIC TREATING AGENT FOR USE AFTER ETCHING, PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJITSU LTD (JP) 2015-05-06 EP disclosed
US-8791221-B2 Addition-curable metallosiloxane compound DAICEL CORPORATION (JP) 2014-07-29 US disclosed
US-8716209-B2 Agent for post-etch treatment of silicon dielectric film, method of manufacturing semiconductor device, and semiconductor device FUJITSU LIMITED (JP) 2014-05-06 US disclosed
EP-2650319-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND Daicel Corporation (JP) 2013-10-16 EP disclosed
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND DAICEL CORPORATION (JP) 2013-10-10 US disclosed
CN-103249762-A Addition-curable metallosiloxane compound DAICEL CORP 2013-08-14 CN disclosed
US-8268489-B2 Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same LG CHEM, LTD. (KR) 2012-09-18 US disclosed
US-20110206999-A1 NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2011-08-25 US disclosed
US-20100007031-A1 AGENT FOR POST-ETCH TREATMENT OF SILICON DIELECTRIC FILM, METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJITSU LIMITED (JP) 2010-01-14 US disclosed
EP-2128897-A1 SILICON DIELECTRIC TREATING AGENT FOR USE AFTER ETCHING, PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE Fujitsu Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267653-A1 ADDITION-CURABLE METALLOSILOXANE COMPOUND B2M, MSI2, MNS1 TSHR 4702/4885ALDH1A1 2073/4885ZDHHC20 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.